Article Details
Retrieved on: 2024-01-23 18:43:02
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article explores the response of the food and health supplement industry to the increasing use of GLP-1 based anti-obesity medications like semaglutide, highlighting tactics such as repositioning existing products, developing new offerings tailored to individuals on these drugs, and leveraging ingredients that naturally boost satiety. Key players like Nestlé and Danone see opportunities for growth, while some remain skeptical about the drugs' long-term impact on consumption patterns. The text connects biopharma to neuropsychology, dietary adjustments, and the business strategies of major retailers in the United States.
Article found on: agfundernews.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here